Organisation paid for research Program year 2025 Source: CMS Open Payments

Austin Neuromuscular Center

Neither a doctor nor a teaching hospital

Research payments

$1,312,430

146 payments

Through program year 2025, Austin Neuromuscular Center is reported as receiving $1,312,430 in research payments, across 146 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $395,121 8
2024 Research $203,559 58
2023 Research $221,293 51
2022 Research $279,680 8
2021 Research $71,428 3
2020 Research $68,201 4
2019 Research $73,149 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $233,393 10 payments
  2. PTC Therapeutics, Inc. $233,098 61 payments
  3. Novartis Pharmaceuticals Corporation $177,252 1 payment
  4. Biogen, Inc. $153,324 3 payments
  5. Alnylam Pharmaceuticals Inc. $135,889 13 payments
  6. Horizon Therapeutics plc $114,145 3 payments
  7. Mitsubishi Tanabe Pharma Development America, Inc. $97,633 4 payments
  8. Alexion Pharmaceuticals, Inc. $62,045 1 payment
  9. Amgen Inc. $61,180 2 payments
  10. Mitsubishi Tanabe Pharma America, Inc. $28,759 25 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis $233,393 10 payments
  2. A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) $177,252 1 payment
  3. A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension $153,324 3 payments
  4. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects Ofptc857in Adult Subjects Withamyotrophic Lateral Sclerosis(Cardinals) $125,362 39 payments
  5. A Phase 3B, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for A Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (Als) $101,232 26 payments
  6. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of Ptc857 in Adult Subjects With Amyotrophic Lateral Sclerosis (Cardinals) $77,196 20 payments
  7. Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis hATTR $70,949 11 payments
  8. A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study With Open-Label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis $68,056 1 payment
  9. Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement Inhibitor Naive Adult Patients With Generalized Myasthenia Gravis $62,045 1 payment
  10. Spectrum of peripheral and Autonomic Neuropathies in patients with wATTR $57,980 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record